Biblio
Intratumoral administration of the immunologic adjuvant AS01 in combination with autologous CD1c (BDCA-1)/CD141 (BDCA-3) myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma. J Immunother Cancer. 2024;12(1).
Mesenchymal stromal cell therapy in haematology: from laboratory to clinic and back again. Stem Cells Dev. 2015.
. . .